Suppression of mTOR via Akt-dependent and -independent mechanisms in seleniumtreated colon cancer cells: Involvement of AMPKα1

Carcinogenesis

Volumn 31, Issue 6, 2010, Pages 1092-1099

  Lee, Yun Kyoung ^a   Park, Song Yi ^a   Kim, Young Min ^a   Kim, Dong Chool ^b   Lee, Won Sup ^b   Surh, Young Joon ^c   Park, Ock Jin ^a  

^a Hannam University Daedeok Valley Campus ^*  (South Korea)

^b Gyeongsang National University School of Medicine   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ALPHA1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; SELENIUM; TUBERIN; UNCLASSIFIED DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; SIGNAL PEPTIDE; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN HT29; COLON CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; EMBRYO; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; COLON TUMOR; DRUG ANTAGONISM; ENZYME ACTIVATION; ENZYMOLOGY; IMMUNOHISTOCHEMISTRY; METABOLISM; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; WESTERN BLOTTING;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BLOTTING, WESTERN; CELL PROLIFERATION; COLONIC NEOPLASMS; ENZYME ACTIVATION; HT29 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING; SELENIUM;

EID: 77953917685     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgq040     Document Type: Article

References (42)

1. Cohen,A. et al. (2009) An amino acid shuffle activates mTORC1. Cell, 136, 399-400.
2. Guertin,D.A. et al. (2005) An expanding role for mTOR in cancer. Trends Mol. Med., 11, 353-361.
3. Sarbassov,D.D. et al. (2005) Growing roles for the mTOR pathway. Curr. Opin. Cell Biol., 17, 596-603.
4. Memmott,R.M. et al. (2009) Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell. Signal., 21, 656-664.
5. Shaw,R.J. et al. (2004) The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell, 6, 91-99.
6. Carretero,J. et al. (2007) Dysfunctional AMPK activity, signaling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer. Oncogene, 26, 1616-1625.
7. Hardie,D.G. (2008) AMPK and Raptor: matching cell growth to energy supply. Mol. Cell, 30, 263-265.
8. Shaw,R.J. (2009) LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol., 1, 65-80.
9. Guo,D. et al. (2009) The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc. Natl Acad. Sci. USA, 106, 12932-12977.
10. Dowling,R.J. et al. (2007) Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res., 67, 10804-10812.
11. Zou,C.Y. et al. (2009) Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor. Mol. Cancer Ther., 8, 1157-1168.
12. Inoki,K. et al. (2003) TSC2 mediates cellular energy response to control cell growth and survival. Cell, 115, 577-590.
13. Corradetti,M.N. et al. (2004) Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev., 18, 1533-1538.
14. Chen,J. et al. (1992) Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation. Science, 257, 1261-1264.
15. Engelman,J.A. (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer, 8, 550-562.
16. Mak,B.C. et al. (2004) The tuberous sclerosis complex genes in tumor development. Cancer Invest., 4, 588-603.
17. Wong,K.K. (2009) Recent developments in anti-cancer agents targeting the Ras/Raf/MEK/ERK pathway. Recent Pat. Anticancer Drug Discov., 1, 28-35.
18. Hwang,J.T. et al. (2006) Selenium regulates cyclooxygenase-2 and extracellular signal-regulated kinase signaling pathways by activating AMP-activated protein kinase in colon cancer cells. Cancer Res., 66, 10057-10063.
19. Jacobs,E.T. et al. (2004) Selenium and colorectal adenoma: results of a pooled analysis. J. Natl Cancer Inst., 96, 1669-1675.
20. Duffield-Lillico,A.J. et al. (2002) Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol. Biomarkers Prev., 11, 630-639.
21. Clark,L.C. et al. (1996) Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA, 276, 1957-1963.
22. Sabatini,D.M. (2006) mTOR and cancer: insights into a complex relationship. Nat. Rev. Cancer, 6, 729-734.
23. Inoki,K. et al. (2002) TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signaling. Nat. Cell Biol., 4, 648-657.
24. Manning,B.D. et al. (2002) Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell, 10, 151-162.
25. Kovacina,K.S. et al. (2003) Identification of a proline-rich Akt substrate as a 14-3-3 binding partner. J. Biol. Chem., 278, 10189-10194.
26. Gulhati,P. et al. (2009) Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer. Clin. Cancer Res., 15, 7207-7216.
27. Zhang,Y.J. et al. (2009) mTOR signaling pathway is a target for the treatment of colorectal cancer. Ann. Surg. Oncol., 16, 2617-2628.
28. Motoshima,H. et al. (2006) AMPK and cell proliferation-AMPK as a therapeutic target for atherosclerosis and cancer. J. Physiol., 1, 63-71.
29. Wang,W. et al. (2009) AMP-activated protein kinase and cancer. Acta Physiol., 196, 55-63.
30. Fay,J.R. et al. (2009) Energy homeostasis and cancer prevention: the AMPactivated protein kinase. Cancer Prev. Res., 2, 301-309.
31. Hahn-Windgassen,A. et al. (2005) Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J. Biol. Chem., 280, 32081-32089.
32. Gwinn,D.M. et al. (2008) AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell, 30, 214-226.
33. Garami,A. et al. (2003) Insulin activation of Rheb, a mediator of mTOR/ S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol. Cell, 11, 1457-1466.
34. Wan,X. et al. (2007) Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene, 26, 1932-1940.
35. O'Reilly,K.E. et al. (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res., 66, 1500-1508.
36. Shi,Y. et al. (2005) Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol. Cancer Ther., 4, 1533-1540.
37. Jin,Q. et al. (2007) Implication of AMP-activated protein kinase and Aktregulated survivin in lung cancer chemopreventive activities of deguelin. Cancer Res., 67, 11630-11639.
38. Kim,K.Y. et al. (2009) Adiponectin-activated AMPK stimulates dephosphorylation of AKT through protein phosphatase 2A activation. Cancer Res., 69, 4018-4026.
39. Cully,M. et al. (2006) Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer, 6, 184-192.
40. Balendran,A. et al. (1999) PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2. Curr. Biol., 9, 393-404.
41. Liu,P. et al. (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov., 8, 627-644.
42. Hennessy,B.T. et al. (2005) Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov., 4, 988-1004.